GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 3,639 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $53.77, for a total value of $195,669.03. Following the completion of the sale, the chief executive officer directly owned 96,123 shares of the company’s stock, valued at approximately $5,168,533.71. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The shares were sold at an average price of $65.19, for a total value of $141,592.68.
• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The shares were sold at an average price of $63.17, for a total value of $2,964,757.61.
• On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total value of $1,319,347.20.

GeneDx Trading Up 12.3%

NASDAQ WGS opened at $60.99 on Friday. The company has a market cap of $1.81 billion, a PE ratio of -22.76 and a beta of 1.96. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The stock has a 50 day moving average of $55.07 and a 200-day moving average of $90.41.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period in the previous year, the company posted ($0.23) EPS. On average, equities research analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund interest may be supportive for sentiment, as reports say Eli Casdin is loading up on GeneDx shares. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms reiterated that a class action has been filed against GeneDx and that investors have until August 3, 2026 to seek lead-plaintiff status. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional notices from Rosen, Faruqi & Faruqi, Schall, Robbins LLP, and others kept the securities-fraud case in the spotlight, reinforcing legal overhang rather than adding new operational news. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares on June 9, though the company said the sales were to cover tax withholding tied to equity vesting. CEO Form 4 Filing

Wall Street Analyst Weigh In

Several research firms have recently commented on WGS. Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the company a “buy” rating in a report on Tuesday, May 5th. Piper Sandler reaffirmed an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Guggenheim cut their price target on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. BTIG Research cut their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Finally, Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $96.43.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in GeneDx during the 4th quarter worth $27,000. Jones Financial Companies Lllp increased its position in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the period. Ramirez Asset Management Inc. bought a new position in GeneDx during the 4th quarter worth $33,000. Greenline Wealth Management LLC bought a new position in GeneDx during the 4th quarter worth $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in GeneDx during the 4th quarter worth $35,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.